Evidence map›Paper›PMID 32556002›Full record

ArticleRevista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)

The future of precision medicine in opioid use disorder: inclusion of patient-important outcomes in clinical trials.

Nitika Sanger, Balpreet Panesar, Tea Rosic, Brittany Dennis, Alessia D'Elia, Alannah Hillmer, Caroul Chawar, Leen Naji, Jacqueline Hudson, M Constantine Samaan and 4 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Nitika SangerMedical Science Graduate Program, McMaster University, Hamilton, ON, Canada.
Balpreet PanesarNeuroscience Graduate Program, McMaster University, Hamilton, ON, Canada.
Tea RosicDepartment of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada.
Brittany DennisDepartment of Medicine, McMaster University, Hamilton, ON, Canada.
Alessia D'EliaNeuroscience Graduate Program, McMaster University, Hamilton, ON, Canada.
Alannah HillmerNeuroscience Graduate Program, McMaster University, Hamilton, ON, Canada.
Caroul ChawarNeuroscience Graduate Program, McMaster University, Hamilton, ON, Canada.
Leen NajiDepartment of Family Medicine, Halton Healthcare, Milton, ON, Canada.
Jacqueline HudsonDepartment of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada.
M Constantine SamaanDepartment of Pediatrics, McMaster University, Hamilton, ON, Canada.
Russell J de SouzaDepartment of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
David C MarshNorthern Ontario School of Medicine, Laurentian University, Sudbury, ON, Canada.
Lehana ThabaneDepartment of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
Zainab SamaanDepartment of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada.ORCID http://orcid.org/0000-0002-5974-9361
McMaster University · CAImpact · CACARE Canada · CALaurentian University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Opioid use has reached an epidemic proportion in Canada and the United States that is mostly attributed to excess availability of prescribed opioids for pain. This excess in opioid use led to an increase in the prevalence of opioid use disorder (OUD) requiring treatment. The most common treatment recommendations include medication-assisted treatment (MAT) combined with psychosocial interventions. Clinical trials investigating the effectiveness of MAT, however, have a limited focus on effectiveness measures that overlook patient-important outcomes. Despite MAT, patients with OUD continue to suffer negative consequences of opioid use. Patient goals and personalized medicine are overlooked in clinical trials and guidelines, thus missing an opportunity to improve prognosis of OUD by considering precision medicine in addiction trials. In this mixed-methods study, patients with OUD receiving MAT (n=2,031, mean age 39.1 years [SD 10.7], 44% female) were interviewed to identify patient goals for MAT. The most frequently reported patient-important outcomes were to stop treatment (39%) and to avoid all drugs (25%). These results are inconsistent with treatment recommendations and trial outcome measures. We discuss theses inconsistencies and make recommendations to incorporate these outcomes to achieve patient-centered and personalized treatment strategies.

Indexed as

Behavior, AddictiveOpioid-Related DisordersAdultAnalgesics, OpioidFemaleHumansMaleOpiate Substitution TreatmentPrecision MedicineUnited StatesAnalgesics, Opioid

Identifiers

PMID32556002
PMCPMC8023161
OpenAlexW3035564334

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.